What Pramlintide is
Pramlintide is an amylin analog that affects post-meal glucose context, satiety signaling, and gastric emptying context.
Pramlintide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it is relevant to appetite and metabolic peptide coverage even though it is not a GLP-1 agonist.
The useful starting point is to separate the molecule itself from the internet story around it. It is relevant to appetite biology even though it is not a GLP-1 drug.
Why people keep looking it up
People bring up pramlintide for satiety and glucose control.
Pramlintide is an amylin analog, a peptide signal involved in post-meal satiety and glucose context.
Pramlintide tends to stay in the conversation because it touches a familiar public theme: amylin analog, satiety, and glucose. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
It is an approved medicine for specific uses, not a casual fat-loss protocol.
Human trials and official labels support approved use in specific diabetes contexts.
Mechanistic rationale follows amylin biology and satiety signaling.
Why this page carries the current tier: Approved peptide drug with official label trail.
The current seed trail for Pramlintide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Use official labeling for risk context and avoid extrapolating to casual fat-loss claims.
FDA-approved pramlintide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Pramlintide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Pramlintide is CID 70691388. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 70691388
- Formula
- C171H267N51O53S2
- Molecular weight
- 3949
- InChIKey
- TZIRZGBAFTZREM-MKAGXXMWSA-N
Matched synonyms include Triproamylin, pramlintida, TRIPRO-AMYLIN, AC0137, AC137, AC-137, AC-0137, D3FM8FA78T.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Pramlintide returns 63 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Pramlintide returns 514 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- SymlinPen
- Generic names
- PRAMLINTIDE ACETATE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA021332
Indications and usage. 1 INDICATIONS AND USAGE SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. SYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin th...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Severe hypoglycemia: Increased risk particularly for type 1 diabetes. Upon initiation of SYMLIN, reduce mealtime insulin dose by 50% and frequently monitor blood glucoses (5.2) . • Never share a SymlinPen between patients, even if the needle is changed (5.3) . • Do not mix SYMLIN and insulin: Mixing can alter the pharmacokinetics of both products. Administer as separate injections (5.4 ,...
Contraindications. 4 CONTRAINDICATIONS SYMLIN is contraindicated in patients with any of the following: • serious hypersensitivity reaction to SYMLIN or to any of its product components. • hypoglycemia unawareness. • confirmed gastroparesis. • Prior serious hypersensitivity reaction to SYMLIN or its ingredients (4) • Hypoglycemia unawareness (4) • Confirmed gastroparesis (4)
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.